|
Reliance Industries Limited
|
|
POLYPROPYLENE
|
| REPOL C015EG |
IMAPACT
COPOLYMER |
| |
| Product description &
applications : |
Features : |
|
REPOL Polypropylene C015EG is manufactured using Unipol
PP process which combines the production efficiency
of gas phase fluidized bed reactor technology with the
high activity and stereo specificity of the SHAC catalyst
system.
REPOL C015EG is recommended for use in
Blow Moulding and Extrusion processes where high impact
strength is required. It is an ideal material for making
blow moulded containers, sheets, automotive trims etc.
|
Repol
C015EG is designed to provide
- Consistent processability
- Good stiffness-impact balance
- Good surface gloss
|
| |
| Typical properties
of Repol C015EG are as follows: |
| |
| Property |
ASTM Test
Method |
Unit |
Typical Value*. |
| Melt flow index,(230oc/2.16Kg) |
D 1238 |
g/10 min |
1.5 |
| Tensile Strength
at yield (50 mm/min ) |
D 638$ |
MPa |
26.5 |
| Elongation at
yield (50 mm/min ) |
D 638$ |
% |
11 |
| Flexural modulus
(1% secant) |
D 790A$ |
MPa |
1000 |
| Notched izod
impact strength (23oc) |
D 256$ |
J/m |
225 |
| Heat deflection
temperature (455 kPa) |
D 648 |
oC |
95 |
| |
|
$ : ASTM D638 Type I specimen injection moulded and
tested in accordance with ASTM D4101.
|
|
|
|
Repol C015EG meets the requirements stipulated in IS
10910-1984 on on "Specification for Polypropylene and
its copolymers for safe use in contact with foodstuffs,
pharmaceuticals, and drinking water". Additives incorporated
in this grade conform to the positive list of constituents
as prescribed in IS-10909-1984.The grade and the additives
incorporated in it also comply with the FDA:CFR Title
21, 177.1520, Olefin polymers.
|
|
|
|
REPOL is the registered trademark for Polypropylene
from Reliance Industries Limited
|
|
|
|
* Typical values with injection moulded specimens,
not to be taken as specification
|
|
The data, information and suggestions contained contained
herein are given purely as a guide. Reliance Industries
Limited and Reliance Group Companies undertake no responsibility
either for the results deriving from their adoption
or for possible position in apparent contrast with existing
patent rights.
|